Mice lacking a liver protein develop chronic inflammation
In experiments with genetically altered mice, overactive immune cells alone did not reproduce the widespread inflammation seen in old animals lacking the protein.
Paper by Huiying Sun, Miao Yu, Ran Xu et al.

Limit: T cell contributions alongside other inflammatory factors were not measured
Edited by Boris Djordjevic · AgingResearch.News
Mice genetically engineered to lack FGL1, a liver-secreted protein, developed chronic inflammation throughout the body as they aged in animal experiments. Signs appeared only in aged animals. They included skin lesions, immune cells entering multiple organs and higher blood levels of inflammation-promoting proteins.
Before inflammation began, adult and middle-aged mice had normal development of T and B cells, two types of immune cells. Their T cells also responded normally to stimulation of their receptors, which detect signals that activate them. Aged mice lacking the protein had overactive T cells. But transferring those cells into recipient mice with unusually few lymphocytes—a group of immune cells—did not reproduce the systemic inflammation. The findings suggested that T cell overactivity was not the primary driver of the condition.
Why it matters
The work addresses how the body keeps immune activity in check with age, and what might account for chronic inflammation that emerges late in life.
Caveats
The transfer experiment tested whether T cells alone could reproduce inflammation, not whether they contributed alongside other factors. The findings came from genetically modified mice, not people.
Where the evidence stands
Inflammation
- 986 independent labs in 73 countries
- 188 findings against
- 1,913 trials, 540 with no results posted
- Funders: National Institutes of Health and others
- 361 of 4,268 findings with company ties
- 1,455 of 1,913 trials sponsored by developers of drugs on it
The paper
Huiying Sun, Miao Yu, Ran Xu et al.
Frontiers in Cell and Developmental Biology, Oct 30, 2026, CC BY, Accepted, not yet published


Comments
Be the first to comment.